

PRODUCT MONOGRAPH  
Including Patient Medication Information

**PrOZURDEX<sup>®</sup>**

(dexamethasone)

Intravitreal Implant 0.7 mg

Corticosteroid

Allergan Inc.  
Markham, ON  
L6G 0B5

**Date of Revision:**  
August 21, 2019

**Submission Control No: 223933**

## Table of Contents

<b>PART I: HEALTH PROFESSIONAL INFORMATION.....</b>	<b>3</b>
SUMMARY PRODUCT INFORMATION .....	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS .....	3
WARNINGS AND PRECAUTIONS.....	4
ADVERSE REACTIONS.....	7
DRUG INTERACTIONS .....	13
DOSAGE AND ADMINISTRATION .....	14
OVERDOSAGE .....	16
ACTION AND CLINICAL PHARMACOLOGY .....	16
STORAGE AND STABILITY .....	17
SPECIAL HANDLING INSTRUCTIONS .....	17
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	17
<b>PART II: SCIENTIFIC INFORMATION .....</b>	<b>18</b>
PHARMACEUTICAL INFORMATION.....	18
CLINICAL TRIALS .....	19
DETAILED PHARMACOLOGY .....	27
TOXICOLOGY .....	28
REFERENCES .....	30
<b>PATIENT MEDICATION INFORMATION.....</b>	<b>34</b>

**PrOZURDEX®**

dexamethasone

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<b>Route of Administration</b>	<b>Dosage Form / Strength</b>	<b>Clinically Relevant Nonmedicinal Ingredients</b>
Intravitreal injection	Intravitreal implant 0.7 mg	None. For complete listing see the Dosage Forms, Composition and packaging section of the Product Monograph

**INDICATIONS AND CLINICAL USE**

OZURDEX® (dexamethasone intravitreal implant 0.7 mg) is indicated for:

- the treatment of macular edema following central retinal vein occlusion (CRVO).
- the treatment of non-infectious uveitis affecting the posterior segment of the eye.
- the treatment of adult patients with diabetic macular edema (DME) who are pseudophakic.

**Geriatrics (> 65 years of age):**

No dose adjustment is required for elderly patients.

**Pediatrics (< 18 years of age):**

OZURDEX® is not recommended for pediatric use. The safety and efficacy of OZURDEX® have not been studied in pediatric patients.

**CONTRAINDICATIONS**

- Patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
- Patients with advanced glaucoma.
- Patients with known hypersensitivity to any components of this product or to other corticosteroids.
- Patients who have aphakic eyes with rupture of the posterior lens capsule.

- Patients with ACIOL (Anterior Chamber Intraocular Lens) and rupture of the posterior lens capsule.

## **WARNINGS AND PRECAUTIONS**

### **General**

There is only very limited information on repeat dosing intervals less than 6 months and there is currently more information on repeat administrations beyond 2 implants in patients with macular edema due to retinal vein occlusion (CRVO). A 2-year observational study has shown that the use of more than two consecutive administrations is associated with increases in some adverse reactions; therefore, for macular edema following CRVO, no more than two consecutive OZURDEX<sup>®</sup> injections should be used, and an interval of approximately 6 months should be allowed between the two injections. (See **DOSAGE AND ADMINISTRATION**).

In patients with posterior segment uveitis, as there is no experience with more than one OZURDEX<sup>®</sup> injection, the use of a second OZURDEX<sup>®</sup> injection is not recommended. Caution should be exercised if a second injection is considered in cases where the possible benefits are believed to outweigh the risk to the patient. An interval of approximately 6 months should be allowed between the two injections.

Patients who experience and retain improved vision should not be retreated. Patients who experience a deterioration in vision, which is not slowed by OZURDEX<sup>®</sup>, should not be retreated.

Repeat doses should only be considered when a patient experiences a response to treatment followed subsequently by a loss in visual acuity and in the physician's opinion may benefit from retreatment without being exposed to significant risk.

OZURDEX<sup>®</sup> has not been studied in patients with macular edema secondary to RVO with significant retinal ischemia, therefore OZURDEX<sup>®</sup> is not recommended in these patients.

The safety and efficacy of OZURDEX<sup>®</sup> administered to both eyes concurrently have not been studied, therefore administration to both eyes is not recommended.

OZURDEX<sup>®</sup> has not been studied in aphakic patients. Therefore, OZURDEX<sup>®</sup> should be used with caution in these patients.

### **Ophthalmologic**

#### **Intravitreal Injection-related Effects:**

OZURDEX<sup>®</sup> must be administered by a qualified ophthalmologist experienced in intravitreal injections. Intravitreal injections have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients in whom the posterior capsule of the lens is absent or has a tear (e.g., occurring after cataract surgery) are at risk of implant migration into the anterior chamber. Proper aseptic injection techniques must always be used.

There have been reports of implant misplacement requiring surgical intervention.

Serious cases of dislocated implants moving into the anterior chamber have been reported, some of which required eye surgery. See ADVERSE REACTIONS - Post-Market Adverse Drug Reactions.

Several cases of hypotony of the eye (associated with vitreous leakage due to injection) were also reported, some of which were serious. See ADVERSE REACTIONS - Post-Market Adverse Drug Reactions.

Patients should be monitored regularly following the injection including monitoring of the perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report any symptoms suggestive of endophthalmitis or any of the above mentioned events without delay. See **DOSAGE AND ADMINISTRATION**.

The most common haemorrhagic adverse reaction reported in patients receiving anti-platelet therapy was conjunctival haemorrhage (24%). OZURDEX<sup>®</sup> should be used with caution in patients taking anti-coagulant or anti-platelet medicinal products. See Drug Interactions.

#### Potential Steroid-related Effects:

Prolonged use of corticosteroids may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and result in secondary ocular infections due to bacteria, fungi, or viruses.

Corticosteroids should be used cautiously in patients with a history of ocular herpes simplex. Corticosteroids should not be used in active ocular herpes simplex.

In clinical studies, cataract was reported more frequently in patients with phakic lens receiving a second injection (see **ADVERSE REACTIONS**). Increase of IOP of  $\geq 10$  mmHg from baseline was also reported with maximum rates at 60 days following the OZURDEX<sup>®</sup> injection. Patients less than 45 years old were more likely to experience IOP increase. Therefore, regular monitoring of IOP is required and any elevation should be managed appropriately post-injection as needed.

OZURDEX<sup>®</sup> is a biodegradable polymer matrix containing 700  $\mu$ g micronized dexamethasone. However, implant residuals were reported in 34% of patients treated with OZURDEX<sup>®</sup> but also in 17% of patients treated with the sham. There does not appear to be residuals accumulation following the second implant. The possible impacts of implant residuals after OZURDEX<sup>®</sup> injection are unknown.

#### Peri-Operative Considerations

The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or

equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection.

### **Sexual Function/Reproduction**

No reproductive and developmental toxicity data are available for OZURDEX<sup>®</sup>. Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application (Pregnancy Category C). Therefore, OZURDEX<sup>®</sup> is not recommended during pregnancy unless the potential benefit justifies the potential risk to the foetus.

### **Special Populations**

#### **Pregnant Women:**

Topical dexamethasone has been shown to be teratogenic in mice (fetal resorptions and cleft palate) and rabbits (fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc). Pregnant rhesus monkeys treated with dexamethasone intramuscularly had fetuses with cranial abnormalities. See Toxicology.

There are no adequate and well-controlled studies in pregnant women. OZURDEX<sup>®</sup> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

#### **Nursing Women:**

It is not known whether ocular administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. OZURDEX<sup>®</sup> is not recommended during breast feeding unless clearly necessary.

#### **Pediatrics (< 18 years of age):**

The safety and effectiveness of OZURDEX<sup>®</sup> has not been studied in pediatric patients.

#### **Geriatrics (> 65 years of age):**

No increased risk in the geriatric population was noted in the clinical studies with OZURDEX<sup>®</sup>.

### **Renal, Hepatic/Biliary/Pancreatic**

No studies have been conducted to examine the pharmacokinetics of OZURDEX<sup>®</sup> in patients with renal, hepatic/biliary/pancreatic impairment.

### **Carcinogenesis and Mutagenesis**

No carcinogenicity studies were performed. See Toxicology.

### **Endocrine and Metabolism**

Disturbances on the corticosteroids HPA axis in humans were not evaluated for OZURDEX<sup>®</sup>.

### **Occupational Hazards**

Patients may experience temporary visual blurring after receiving OZURDEX<sup>®</sup> by intravitreal injection. They should not drive or use machines until this has resolved.

## **ADVERSE REACTIONS**

### **Adverse Drug Reaction Overview**

Adverse reactions related to the prolonged use of ophthalmic dexamethasone include increased intraocular pressure (IOP), glaucoma with possible damage to the optic nerve, defects in visual acuity and visual field, posterior subcapsular cataract formation, secondary ocular infection from pathogens (including herpes simplex), and perforation of the globe where there is thinning of the cornea or sclera.

### **Indication of Macular Edema due to CRVO**

In two phase 3 studies assessing OZURDEX<sup>®</sup>, the most frequently reported adverse reactions with OZURDEX<sup>®</sup> were increased IOP (25.2 %) and conjunctival haemorrhage (20.2 %). Cataracts were also observed with OZURDEX<sup>®</sup>. Other events reported infrequently and believed to be due to the procedure included vitreous hemorrhage and conjunctival edema. Overall, a total of 62.9 % of patients experienced at least one adverse reaction based on the investigator's assessment.

Following the second OZURDEX<sup>®</sup> injection, the adverse event profile was similar to that following the first injection, except for the overall incidence of cataracts which increased significantly after one year, with subcapsular cataract reported in 13% of patients.

No significant differences in the safety profile were noted between patients with CRVO and those with BRVO, in relation to OZURDEX<sup>®</sup>.

### **Indication of Posterior Segment Uveitis**

In a single 6-month randomized study in adult patients with posterior segment uveitis, 76 patients received OZURDEX<sup>®</sup> (with 73 completing the 6-month follow-up), and 75 patients received a sham. Fifty-seven (57) patients with OZURDEX<sup>®</sup> (75%) experienced ocular adverse events, as compared to 60% of those with the sham. The most frequently reported adverse events were increased IOP (25 % with OZURDEX<sup>®</sup> and 7% with the sham) and conjunctival haemorrhage (30% with OZURDEX<sup>®</sup> and 21% with sham). Cataract was reported in 12% of patients with OZURDEX<sup>®</sup> and 5% of those with the sham. Other events included ocular discomfort, eye pain, and ocular hypertension. See table 2 below for less common adverse events.

### **Indication of Diabetic Macular Edema**

In two phase 3 studies assessing OZURDEX<sup>®</sup>, the most frequently reported adverse reactions with OZURDEX<sup>®</sup> were cataracts (37.8%), intraocular pressure increased (30.8%), and conjunctival haemorrhage (21.0%). Incidences were generally higher with dexamethasone compared to sham, however there were no notable differences between the OZURDEX<sup>®</sup> and DEX 350- $\mu$ g doses. Of note, cumulative study exposure (ie, patient years) was shorter in the sham group (665.5 patient years) than in the OZURDEX<sup>®</sup> and DEX 350 groups (853.9 and 880.2 patient years, respectively) due to more patient discontinuations after the second treatment

in the sham group. Overall incidences of AEs and SAEs were similar across all three groups by exposure-adjusted analysis

### **Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

#### **Indication of Macular Edema due to CRVO**

The following information in Table 1 is based on the combined clinical trial results from the initial 6 month masked period of two, multicenter, double-masked, randomized, sham-controlled, parallel studies in patients with macular edema due to BRVO or CRVO. Overall, 427 were randomized to receive OZURDEX® and 426 to receive a sham. A total of 401 patients (94%) randomized and treated with OZURDEX® completed the initial treatment period (up to day 180).

**Table 1 Adverse Drug Reactions (>2%) after 6 Months Following One OZURDEX® Injection**

MedDRA term	OZURDEX® N=421(%)	Sham N=423(%)
<b>Ocular Reactions in the study eye</b>		
Intraocular pressure increased	106 (25.2%)	5 (1.2%)
Conjunctival hemorrhage	85 (20.2%)	63 (14.9%)
Eye pain	31 (7.4%)	16 (3.8%)
Conjunctival hyperemia	28 (6.7%)	20 (4.7%)
Ocular hypertension	17 (4.0%)	3 (0.7%)
Cataract <sup>(*)</sup>	15 (3.6%)	6 (1.4%)
Vitreous detachment	12 (2.9%)	8 (1.9%)
<b>Non-ocular Reactions</b>		
Headache	14 (3.3%)	7 (1.7%)

<sup>(\*)</sup> Following two OZURDEX® injections, cataracts were reported in **26%** of patients, with subcapsular cataracts reported in **13%** of patients.

Following the first OZURDEX® injection, increased IOP with OZURDEX® peaked at day 60 and returned to baseline levels by day 180. Elevations of IOP either did not require treatment or were managed with topical IOP-lowering medications. During the initial treatment period, 0.7% (3/421) of the patients who received OZURDEX® required laser or surgical procedures for management of elevated IOP in the study eye compared with 0.2% (1/423) with sham.



In 341 patients analyzed following a second injection of OZURDEX® (6-month open-label phase), the increase in IOP was similar to the increase that was seen following the first injection during initial 6-month randomized phase, and likewise returned to baseline by the end of the 6-month open-label phase. However, compared to the initial 6 months, the overall incidence of cataracts was higher after 1 year, compared to the initial 6 months with subcapsular cataract reported in 13% of patients.

The adverse event profile for BRVO patients was similar to that observed for CRVO patients. Although, the overall incidence of adverse events was higher for patients with CRVO (79.7%) than BRVO (69.1%), there was no indication that OZURDEX® was more frequently associated with the occurrence of AEs in patients with CRVO than in patients with BRVO. That is, the difference in percentage of patients with AEs (overall) between OZURDEX® and sham was approximately 19% for patients with CRVO, and 14% for those with BRVO.

#### Indication of Posterior Segment Uveitis

The following information in Table 2 is based on results from a 6-month randomized, sham-controlled study assessing the effects of a single OZURDEX® injection in the treatment of patients with posterior segment uveitis:

**Table 2      Ocular adverse events reported by ≥ 2% of patients with OZURDEX®**

<b>MedDRA Preferred Term</b>	<b>OZURDEX® N = 76</b>	<b>Sham N = 75</b>
Overall Ocular adverse events	57 (75.0%)	45 (60.0%)
IOP increased	19 (25.0%)	5 (6.7%)
Conjunctival Haemorrhage	23 (30.3%)	16 (21.3%)
Ocular Discomfort	10 (13.2%)	6 (8.0%)
Eye Pain	9 (11.8%)	10 (13.3%)
Cataract	11 (14.5%)	8 (10.7%)
Iridocyclitis	7 (9.2%)	4 (5.3%)
Ocular Hypertension	6 (7.9%)	0
Myodesopsia	6 (7.9%)	5 (6.7%)
Uveitis	6 (7.9%)	7 (9.3%)
Vision Blurred	5 (6.6%)	3 (4.0%)
Conjunctival Hyperaemia	5 (6.6%)	7 (9.3%)
Blepharitis	3 (3.9%)	0
Vitreous Opacities	3 (3.9%)	1 (1.3%)
Intermediate Uveitis	3 (3.9%)	1 (1.3%)
Conjunctival Oedema	3 (3.9%)	3 (4.0%)
Eye Irritation	3 (3.9%)	3 (4.0%)
Eye Pruritus	3 (3.9%)	5 (6.7%)
Macular Oedema	3 (3.9%)	6 (8.0%)
Iritis	2 (2.6%)	0

<b>MedDRA Preferred Term</b>	<b>OZURDEX® N = 76</b>	<b>Sham N = 75</b>
Maculopathy	2 (2.6%)	0
Anterior Chamber Cell	2 (2.6%)	1 (1.3%)
Dry Eye	2 (2.6%)	1 (1.3%)
Photopsia	2 (2.6%)	1 (1.3%)
Scleral Hyperaemia	2 (2.6%)	1 (1.3%)
Visual Impairment	2 (2.6%)	1 (1.3%)
Abnormal sensation in eye	2 (2.6%)	0
Eyelids Pruritus	2 (2.6%)	0
Retinal Detachment	2 (2.6%)	2 (2.7%)

Rates of adverse events of increased IOP with OZURDEX® peaked at week 8 and IOP returned to baseline by week 26. During the treatment period, 25 patients treated with OZURDEX® experienced IOP increases  $\geq 10$  mm Hg, most of which were controlled with topical IOP-lowering medications. However, three patients with elevated IOP required laser iridotomies in the study eye (pupillary block, iris bombe, and raised IOP).

Cataract surgery was performed in one patient with OZURDEX®.

#### Indication of Diabetic Macular Edema

The following information in Table 3 is based on the clinical safety of OZURDEX® which was assessed in 2 phase 3 randomized, masked, sham-controlled studies in patients with diabetic macular edema. In both studies, a total of 347 patients were randomized and received OZURDEX® and 350 received sham.

**Table 3 Summary of Adverse Reactions in Phase 3 Studies in  $\geq 2\%$  of Patients – 3 Year Studies**

	<b>OZURDEX® N = 347</b>	<b>Sham N = 350</b>
<i>Eye Disorders (Study Eye)</i>		
Cataract	131 (37.8%)	34 (9.7%)
Cataract subcapsular	41 (11.8%)	12 (3.4%)
Cataract nuclear	18 (5.2%)	8 (2.3%)
Lenticular opacities	16 (4.6%)	4 (1.1%)
Intraocular pressure increased	107 (30.8%)	12 (3.4%)
Ocular hypertension	21 (6.1%)	5 (1.4%)
Conjunctival haemorrhage*	73 (21.0%)	45 (12.9%)
Vitreous haemorrhage*	24 (6.9%)	25 (7.1%)
Eye pain*	18 (5.2%)	13 (3.7%)
Vitreous detachment*	17 (4.9%)	8 (2.3%)

	OZURDEX® N = 347	Sham N = 350
<i>Eye Disorders (Study Eye)</i>		
Vitreous floaters*	17 (4.9%)	7 (2.0%)
Conjunctival oedema*	15 (4.3%)	4 (1.1%)
Vitreous opacities*	11 (3.2%)	3 (0.9%)

Note: “\*” indicates adverse drug reactions considered to be related to the intravitreal injection procedure.

### Cataract and Intraocular Pressure

At baseline, the percentage of patients who had a phakic study eye was 75.5% (262/347) in the OZURDEX® group and 71.6% (249/348) in the sham group. Among those, 87% in the OZURDEX® group and 83.9% in the sham group had pre-existing lens opacification. The incidence of cataract (i.e., cataract cortical, cataract diabetic, cataract nuclear, cataract subcapsular, lenticular opacities, cataract) in patients who had a phakic study eye was higher in the OZURDEX® group (67.9%) compared with sham (20.4%). 59.2% of patients who had a phakic study eye treated with OZURDEX® required cataract surgery compared to 7.2% of the sham-treated patients with the majority of cataract surgeries reported in the 2<sup>nd</sup> and 3<sup>rd</sup> years.

The mean time to cataract being reported as an adverse event was approximately 16 months in the OZURDEX® group and approximately 10 months in the sham group. In OZURDEX® treated patients with a phakic study eye at baseline, the visual acuity achieved prior to cataract was re-established upon removal of the cataract.

In the OZURDEX® group, the rate of the adverse event of increased IOP did not increase from year to year.

Mean IOP in the study eye at baseline was the same in both treatment groups (15.3 mm Hg). The mean increase from baseline did not exceed 3.2 mm Hg across all visits in the OZURDEX® group, with mean IOP peaking observed at the 1.5 month visit post injection, and returning to approximately baseline levels by month 6 following each injection.

27.7% (96/347) of patients in the OZURDEX® group, and 3.7% (13/350) patients in the sham group had a  $\geq 10$  mm Hg IOP increase from baseline at one or more visits during the study. At month 6 after each treatment,  $\leq 1\%$  of patients in each group had a  $\geq 10$  mm Hg IOP increase from baseline.

6.6% (23/347) of patients in the OZURDEX® group, and 0.9% (3/350) patients in the sham group had IOP  $\geq 35$  mm Hg in the study eye at 1 or more visits during the study). At month 6 after each treatment, no more than 1 patient in each group had IOP  $\geq 35$  mm Hg.

Elevations of IOP were more prevalent in the OZURDEX® group than in the sham group. Overall, 3.5% of patients required IOP-lowering medication(s) at baseline. In total, the collective proportion of patients who were prescribed a topical IOP-lowering medication(s) at any given point in time during year 1 was 32.9%, decreasing to 29.5% and 28.7% throughout the study periods of year 2 and 3 respectively. Of the final visit study population, 21.5% had

been prescribed IOP-lowering medication(s).

One patient in the OZURDEX<sup>®</sup> group required incisional surgery (trabeculectomy) to manage the steroid-induced IOP elevation.

Three patients in the OZURDEX<sup>®</sup> group and one in the sham group had concurrent procedures in the study eye for the treatment of IOP elevation. One patient had a trabeculectomy owing to anterior chamber fibrin blocking the aqueous outflow leading to increased IOP, 2 patients had an iridectomy (1 OZURDEX<sup>®</sup> and 1 sham), and 1 had an iridotomy. No patient required removal of the implant by vitrectomy to control IOP.

In summary, in the OZURDEX<sup>®</sup> group, the incidence of elevated intraocular pressure adverse events did not increase over time, the magnitude of the IOP elevation following OZURDEX<sup>®</sup> treatment did not increase upon repeated injection, and the proportion of patients using IOP-lowering medications in the study eye remained similar from year to year. These data suggest that there is no cumulative effect of OZURDEX<sup>®</sup> on IOP.

### **Less Common Clinical Trial Adverse Drug Reactions (<2%)**

#### **Indication of Macular Edema due to CRVO**

Adverse drug reactions observed at an incidence of <2% in the two controlled clinical trials are provided below:

**Ocular:** Retinal tear\*, anterior chamber flare\*, visual disturbance, photopsia\*, conjunctival edema\*, vitreous hemorrhage\*, vitreous opacities\* (including vitreous floaters), anterior chamber cell\*.

\* considered to be related to the intravitreal injection procedure rather than the dexamethasone implant

#### **Indication of Posterior Segment Uveitis**

OZURDEX<sup>®</sup>-related sterile endophthalmitis was reported in one patient. One case for each of the following events were reported in patients treated with OZURDEX<sup>®</sup>: visual acuity reduced, choroiditis, visual field defect, hypotony of the eye, eye swelling / edema / erythema, eyelid ptosis, conjunctivitis allergic, anterior chamber flare, medical device complication (clot around an end of the study medication implant), and periorbital haematoma.

#### **Indication of Diabetic Macular Edema**

Uncommon adverse reactions included anterior chamber inflammation (1.7% - injection procedure related), endophthalmitis (0.6% - injection procedure related), glaucoma (0.9%) and necrotizing retinitis (0.3%).

### **Post-Market Adverse Drug Reactions**

Reports of pain on injection associated with what was considered to be a blunt needle have been received. Reports of endophthalmitis considered to be injection related have been received (See **WARNINGS AND PRECAUTIONS, Ophthalmologic**).

Serious cases of implants dislocation into the anterior chamber (with or without corneal edema) have been reported.

Failures to insert the implant correctly (misplaced implants) with complications resulting in ocular tissue injury have been reported, and may require eye surgery (cataract surgery) and to remove surgically the implant.

Several cases of temporary hypotony of the eye have been reported, some of which were serious.

Reports of serious ocular hypertension requiring surgery (including vitrectomy to remove the implant) have been reported.

One report of serious vitreous adhesions with foveal traction syndrome has been reported.

Several cases of retinal detachment have been reported, some of which were serious.

#### Post-Marketing Observational Study (CONSTANCE 206207-025)

The clinical safety of DEX 700 was assessed in a multicenter, 24-month real world observational study in the treatment of macular edema following RVO and non-infectious uveitis affecting the posterior segment of the eye. The most frequent adverse reactions observed in this study were consistent with the most frequent adverse reactions from clinical trials. Stratifications by injection frequency revealed increases in the incidence of adverse reactions among patients who received >2 injections compared to patients who received ≤2 injections. The most frequent adverse reactions for patients who received >2 injections included cataract [(24.7%, 44/178) for cataract formation and (32.0%, 57/178) for cataract progression] based on eyes with phakic lens status at baseline, vitreous hemorrhage (6.0%, 17/283), and increased IOP (24.0%, 68/283).

## **DRUG INTERACTIONS**

### **Overview**

Drug interaction studies have not been conducted with OZURDEX®.

Anti-coagulant therapy was used in 1.7% of patients with macular edema due to retinal vein occlusion; there were no reports of hemorrhagic adverse events in these patients. Anti-platelet medicinal products, such as clopidogrel, were used at some stage during the clinical studies in over 40% of patients. In clinical trial patients receiving anti-platelet therapy, haemorrhagic adverse events were reported in a higher proportion of patients injected with OZURDEX® (27%) compared with the control group (20%). The most common haemorrhagic adverse reaction reported was conjunctival haemorrhage (24%). Anti-coagulant or anti-platelet therapy should not be used within two weeks before the injection of OZURDEX®. OZURDEX® should be used with great caution in patients taking anti-coagulant or anti-platelet medicinal products, and only if the expected benefits outweigh the potential risks to the patient.

Systemic drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration.

Plasma dexamethasone concentration following intravitreal administration of OZURDEX<sup>®</sup> is expected to be significantly lower (at or below the limit of detection) compared to oral and IV administration, and therefore, is not expected to result in significant drug-drug interaction systemically.

### **Drug-Food, Drug-Herb, Drug-Laboratory Interactions**

Drug-Food, Drug-Herb, and Drug-Laboratory interactions were not studied.

## **DOSAGE AND ADMINISTRATION**

### **Dosing Considerations**

FOR OPHTHALMIC INTRAVITREAL INJECTION ONLY.

OZURDEX<sup>®</sup> must be administered by a qualified ophthalmologist experienced in intravitreal injections.

Administration to both eyes concurrently is not recommended.

Patients should be monitored following the injection to permit early treatment if an infection or increased intraocular pressure occurs.

Dosing of OZURDEX<sup>®</sup> (dexamethasone intravitreal implant 0.7 mg) is recommended when there is evidence of macular edema or vascular leakage in the macula.

Dosing of OZURDEX<sup>®</sup> is also recommended when there is evidence of non-infectious uveitis affecting the posterior segment of the eye.

OZURDEX<sup>®</sup> should not be used in patients with:

- active or suspected ocular or periocular infections (See **CONTRAINDICATIONS**).
- advanced glaucoma.
- aphakic eyes with rupture of the posterior lens capsule
- anterior chamber intraocular lens and rupture of the posterior lens capsule
- known hypersensitivity to any components of this product or to other corticosteroids.

### **Recommended Dose and Dosage Adjustment**

The recommended dose for the treatment of macular edema following Central Retinal Vein

Occlusion (CRVO) is one OZURDEX<sup>®</sup> implant (entire contents of one single use OZURDEX<sup>®</sup> 0.7 mg device).

The recommended dose for the treatment of adult patients with non-infectious uveitis of the posterior segment of the eye is 700 µg per eye (entire contents of single use OZURDEX<sup>®</sup> 0.7 mg device).

The recommended dose for the treatment of diabetic macular edema is 700 µg per eye (entire contents of single use OZURDEX<sup>®</sup> 0.7 mg device).

Reinjection of OZURDEX<sup>®</sup> for diabetic macular edema is recommended when there is a presence of macular edema (see **Clinical Studies**).

There is only very limited information on repeat dosing intervals less than 6 months (see CLINICAL TRIALS) and there is currently more information on repeat administrations beyond 2 implants for CRVO and uveitis. A 2-year observational study has shown that the use of more than two consecutive administrations is associated with increases in some adverse reactions; therefore, no more than two consecutive OZURDEX<sup>®</sup> injections should be used, and an interval of approximately 6 months should be allowed between the two injections.

Patients who experience and retain improved vision should not be retreated. Patients who experience a deterioration in vision, which is not slowed by OZURDEX<sup>®</sup>, should not be retreated.

Repeat doses should only be considered when a patient experiences a response to treatment followed subsequently by a loss in visual acuity and in the physician's opinion may benefit from retreatment without being exposed to significant risk.

### **Missed Dose**

Missed dose with OZURDEX<sup>®</sup> has not been reported in clinical trials and would not be expected due to its method of administration.

### **Administration**

Single-use intravitreal implant in applicator for intravitreal use only. Each applicator can only be used for the treatment of a single eye.

The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Disinfection of the periocular skin, eyelid, and ocular surface (including drops of povidone iodine 5% solution on the conjunctiva) and administration of adequate local anesthesia and are recommended prior to the injection.

Remove the foil pouch from the carton and examine for damage. Then, in a sterile field, open the foil pouch and gently place the applicator on a sterile tray. Carefully remove the cap from the applicator. Hold the applicator in one hand and pull the safety tab straight off the applicator.

**Do not twist or flex the tab.** The long axis of the applicator should be held parallel to the limbus, and the sclera should be engaged at an oblique angle with the bevel of the needle up (away from the sclera) to create a shelved scleral path. The tip of the needle is advanced within the sclera for about 1 mm (parallel to the limbus), then redirected toward the center of the eye and advanced until penetration of the sclera is completed and the vitreous cavity is entered. The needle should not be advanced past the point where the sleeve touches the conjunctiva. Slowly depress the actuator button until an audible click is noted. Before withdrawing the applicator from the eye, make sure that the actuator button is fully depressed and has locked flush with the applicator surface. Remove the needle in the same direction as used to enter the vitreous.

Immediately after injecting OZURDEX<sup>®</sup>, use indirect ophthalmoscopy in the quadrant of injection to confirm successful implantation. Visualization is possible in the large majority of cases. In cases in which the implant cannot be visualized, take a sterile cotton applicator and lightly depress over the injection site to bring the implant into view.

Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection.

Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay.

## **OVERDOSAGE**

Overdose with OZURDEX<sup>®</sup> (dexamethasone intravitreal implant 0.7 mg) has not been reported in clinical trials and would not be expected due to its method of administration.

## **ACTION AND CLINICAL PHARMACOLOGY**

### **Mechanism of Action**

Dexamethasone is a glucocorticoid receptor agonist. Although the mechanism of action of dexamethasone in ocular inflammatory disease is most likely due to its potent anti-inflammatory activity, the mechanism of action in the treatment of posterior segment diseases is not completely understood. However, dexamethasone has been reported to inhibit the expression of vascular endothelial growth factor (VEGF), a potent promoter of vascular permeability.

### **Pharmacodynamics**

OZURDEX<sup>®</sup> is a biodegradable polymer matrix containing 700 µg micronized dexamethasone placed directly into the posterior segment of the eye with an applicator. The polymer degrades over time, gradually releasing dexamethasone directly to the vitreous, and therefore, OZURDEX<sup>®</sup> may reduce the potential for systemic effects compared with other routes of administration.



### **Pharmacokinetics**

Plasma concentrations were obtained from a subset of 21 patients in the two, 6-month RVO efficacy studies prior to dosing and on day 7, 30, 60, and 90 following the intravitreal implant containing 700 µg dexamethasone. Eighty-six percent of the plasma dexamethasone concentration values for the 700 µg dose group were below the lower limit of quantitation (0.05 ng/mL). The highest plasma concentration value of 0.094 ng/mL was observed in one subject from the 700 µg group. Plasma dexamethasone concentration did not appear to be related to age, body weight, or sex of patients.

In the phase 3 DME studies, blood samples were obtained from a subgroup of patients at predose, days 1, 7, and 21, and months 1.5 and 3 to determine plasma dexamethasone concentrations. In both studies, the majority of concentrations were below the LLOQ of 0.05 ng/mL. Plasma dexamethasone concentrations from 5 of 52 samples in the OZURDEX<sup>®</sup> group and from 0 of 60 samples in the DEX 350 group were above the LLOQ, ranging from 0.0599 ng/mL to 0.102 ng/mL.

In an in vitro metabolism study, following the incubation of [14C]-dexamethasone with human cornea, iris-ciliary body, choroid, retina, vitreous humor, and sclera tissues for 18 hours, no metabolites were observed.

### **STORAGE AND STABILITY**

Store at controlled room temperature 15° -30° C and protected from excessive heat.

### **SPECIAL HANDLING INSTRUCTIONS**

None.

### **DOSAGE FORMS, COMPOSITION AND PACKAGING**

OZURDEX<sup>®</sup> (dexamethasone intravitreal implant 0.7 mg) is a biodegradable intravitreal implant containing 700 µg dexamethasone in a solid polymer drug delivery system. OZURDEX<sup>®</sup> is preloaded into a sterile, single-use, specially designed drug delivery system applicator to facilitate injection of the rod-shaped implant directly into the vitreous. The polymer drug delivery system contains PLGA biodegradable polymer matrix (NOVADUR<sup>™</sup>): Resomer<sup>®</sup> RG 502, Poly (D,L-lactide-co-glycolide), 50:50 PLGA ester terminated; and Resomer<sup>®</sup> RG 502 H, Poly (D,L-lactide-co-glycolide),50:50 PLGA acid terminated. OZURDEX<sup>®</sup> is preservative-free.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION


#### Drug Substance

Proper name: dexamethasone

Chemical name: pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11 $\beta$ ,16 $\alpha$ )

Molecular formula and molecular mass: C<sub>22</sub>H<sub>29</sub>FO<sub>5</sub> and 392.47

Structural formula:



Physicochemical properties: Dexamethasone occurs as a white to cream-colored crystalline powder having not more than a slight odor, and is practically insoluble in water and very soluble in alcohol.

Polymorphism: Polymorph Form B.

Melting Range: The anhydrous dexamethasone crystalline melts at a temperature range of 253-255°C (onset).

Optical Rotation: A one percent dexamethasone solution (m/V) in dioxane displays a specific rotation between +72° and +80° at 25°C.

## CLINICAL TRIALS

### Study demographics and trial design

#### Indication of Macular Edema due to CRVO

**Table 4**                      **Summary of Patient Demographics for 2 Phase 3 Studies, 206207-008 and 206207-009**

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n=number)	Mean age (Range)	Gender
206207-008	Multicentre, masked, randomized, sham-controlled, parallel groups	OZURDEX® 0.7 mg and Dexamethasone 0.35 mg applicator system; and sham needleless applicator system  Intravitreal injection  6-month masked initial treatment followed by 6-month open-label extension	n = 599  OZURDEX® 0.7 mg = 201  Dexamethasone 0.35 mg = 196  Sham = 202	65.5 years  (32 to 91)	M 327  (54.6%)  F 272  (45.4%)
206207-009	Multicentre, masked, randomized, sham-controlled, parallel groups	OZURDEX® 0.7 mg and Dexamethasone 0.35 mg applicator system; and sham needleless applicator system  Intravitreal injection  6-month masked initial treatment followed by 6-month open-label extension	n = 668  OZURDEX® 0.7 mg = 226  Dexamethasone 0.35 mg = 218  Sham = 224	63.6 years  (31 to 96)	M 350  (52.4%)  F 318  (47.6%)

In two identical studies (study 206207-008 and study 206207-009), 1267 adult patients with either CRVO (approximately 1 third of the patients) or BRVO (approximately 2 thirds of the patients) were randomized to OZURDEX® 0.7 mg (n=427), or a Sham (n=426), or to a lower strength dexamethasone implant 0.35 mg (n=414).

The main selection criteria were: A duration of macular edema prior to baseline of 6 weeks to 9 months for CRVO patients and of 6 weeks to 12 months for BRVO patients, Best Corrected Visual Acuity (BCVA) score was between 34 and 68 letters (EDTRS), and Central retinal thickness  $\geq$  300  $\mu$ m by OCT. Note that patients with significant retinal ischemia were not allowed into the study.

After OZURDEX<sup>®</sup> injection, patients were monitored from initial treatment through to day 180 including scheduled visits on days 30, 60, 90, and 180.

At the end of the first 6-month period, patients were eligible to receive a second OZURDEX<sup>®</sup> implant in a 6 month open label extension if they had a BCVA < 84 letters, or a central retinal thickness > 250 µm.

Indication of Posterior Segment Uveitis

**Table 5 Summary of patient demographics for 1 phase 3 Study, 206207-014**

<b>Study #</b>	<b>Trial design</b>	<b>Dosage, route of administration and duration</b>	<b>Study subjects (n=number)</b>	<b>Mean age (Range)</b>	<b>Gender</b>
206207-014	Multicentre, masked, randomized, randomized patient and examiner-masked sham control	OZURDEX <sup>®</sup> and 350 µg applicator system; and sham needleless applicator system Intravitreal injection 8 weeks with an 18-week masked extension	OZURDEX <sup>®</sup> n = 77 DEX 350 = 76 Sham = 76	44.8 years (18 to 82)	M 84 (36.7%) F 145 (63.3%)

In a single, multicenter, masked, randomized study for the treatment of non-infectious uveitis affecting the posterior segment of the eye (study 206207-014), 229 adult patients were randomized to receive either OZURDEX<sup>®</sup> (N = 77), or Sham (N = 76), or a lower strength dexamethasone implant 0.35 mg (n=76). Most patients had intermediate uveitis (80%), and only 20% had posterior uveitis.

Inclusion criteria included a best-corrected (ETDRS) visual acuity score of 10 to 75 letters inclusive (Snellen equivalent approximately 20/640 – 20/32) in the study eye.

Main exclusion criteria were IOP > 21 mm Hg, ocular hypertension or glaucoma, use of anti glaucoma medications ≤ 4 weeks prior to treatment, periocular corticosteroid injections ≤ 8 weeks prior to treatment, intravitreal injections ≤ 26 weeks prior to treatment, previous use of Retisert<sup>™</sup>, and intraocular surgery ≤ 90 days prior to treatment. Other exclusion criteria included history of pars plana vitrectomy or herpetic infection, and presence of active ocular infection, or scleral thinning (or ectasia), uncontrolled systemic disease or HIV infection. Women who were pregnant, nursing, or planning a pregnancy, or who were of childbearing potential and not using contraception, were also excluded.

The primary efficacy analysis was the proportion of patients with vitreous haze score of 0 at

week 8 (primary time point). Other analyses included the proportion of patients with  $\geq 15$ -letter visual score (BCVA) improvement, and the proportion of patients with  $\geq 2$ -unit improvement from baseline in vitreous haze score.

The mean (range) age was 44.8 (18 to 82) years, and 8.3% were over the age of 65 years. The majority of patients were female (63.3%) and Caucasian (60.7%).

Indication of Diabetic Macular Edema (DME)

**Table 6 Summary of Patient Demographics for 2 Phase 3 Studies, 206207-010 and 206207-011**

Study #	Trial design	Dosage, route of administration and duration	# Patients by Arm Entered into ITT/ Completed	Mean age (Range)	Gender
206207-010	Multicentre, masked, randomized, sham-controlled	OZURDEX® 0.7 mg and Dexamethasone 0.35 mg applicator system; and sham needleless applicator system  Intravitreal injection  Up to 7 treatments during the 3-year study period	OZURDEX® 163/107  DEX 350 166/118  Sham 165/70	63.0 years (26 to 84)	<b>M</b> 304 (61.5%)  <b>F</b> 190 (38.5%)
206207-011	Multicentre, masked, randomized, sham-controlled	OZURDEX® 0.7 mg and Dexamethasone 0.35 mg applicator system; and sham needleless applicator system  Intravitreal injection  Up to 7 treatments during the 3-year study period	OZURDEX® 188/118  DEX 350 181/112  Sham 185/82	61.9 years (25 to 88)	<b>M</b> 332 (59.9%)  <b>F</b> 222 (40.1%)

The phase 3 studies included elements necessary for a valid ascertainment of the effectiveness of treatment. A parallel-group design minimized possible confounding effects that are inherent in other study designs (e.g., crossover). The studies were randomized and masked to minimize investigator and patient bias.

Patients were randomized in a 1:1:1 ratio to OZURDEX®, DEX 350, or sham on day 0, and received up to 7 treatments during the 3-year study period. Starting from the month 6 visit, patients were evaluated for retreatment eligibility every 3 months, but the study treatment

procedure was not to be performed more often than approximately every 6 months.

Patients who had confirmed 15 or more letters decrease in BCVA from baseline in the study eye attributable to macular edema (eg, not due to cataract or media opacity) were exited from the study at the investigator's discretion and considered to be a treatment failure. Patients who had received escape therapy in the study eye were considered to be study treatment failures, were no longer eligible to receive study medication, and were withdrawn from the study based on when they last received study treatment. A patient may have been withdrawn from the study at either the patient or the investigator's discretion at any point for any reason. Patients who underwent cataract surgery were to continue in the study.

Patients were masked to the study treatment assignment which was maintained for the duration of the trial. Study treatment procedures and postinsertion safety evaluations were performed by a treating investigator at each site. Follow-up investigators, site personnel including the visual acuity examiner, optical coherence tomography (OCT)/fluorescein angiography technicians, and evaluators at the central reading facility were masked, and had no knowledge of study treatment assignment.

Key inclusion criteria for the phase 3 studies were male or female, at least 18 years of age, diagnosis of diabetes mellitus (type 1 or type 2), blood HbA1c >10%, clinically observable macular edema involving the center of the macula (fovea) associated with diabetic retinopathy, BCVA score between 34 and 68 letters in the study eye, and retinal thickness of  $\geq 300$   $\mu\text{m}$  by OCT.

Further analyses were performed on 187 patients in the ITT population with a pseudophakic lens in the study eye at baseline; 86 in the DEX 700 group and 101 in the Sham group. The baseline characteristics of the pseudophakic subpopulation and the ITT population were generally similar, including mean BCVA (55.5 vs. 56.2 letters, respectively) and central retinal thickness (462.7 vs. 463.6 microns, respectively).

## **Study results**

### **Indication of Macular Edema due to CRVO**

Demographic and baseline characteristics were not significantly different among the treatment groups. Approximately 50% of patients were over 65, and 75% were Caucasian. For the majority of patients, the duration of macular edema was between 90 and 179 days, with 17% of patients with durations less than 90 days.

The efficacy of OZURDEX<sup>®</sup> was assessed based on patients treated with OZURDEX<sup>®</sup> (N=427) as compared to sham (N=426), using the study eye and the ITT population (with Last Observation Carried Forward for missing values). Efficacy analyses were performed separately for CRVO patients and BRVO patients. Among 570 patients with macular edema (ME) due to BRVO, 291 were randomized to OZURDEX<sup>®</sup>, and 279 to sham, and among 283 patients with ME due to CRVO, 136 were randomized to OZURDEX<sup>®</sup>, and 147 to sham.

The treatment benefits of OZURDEX<sup>®</sup> were larger in patients with macular edema due to

CRVO, as compared to those with BRVO. Only results in CRVO patients are presented below.

OZURDEX<sup>®</sup> injection showed a statistically significantly greater proportion of patients achieving a  $\geq 15$ -letter improvement from baseline in Best Corrected Visual Acuity (BCVA) at day 30, and 60.

**Table 7 Proportion of Patients with  $\geq 15$  Letters Improvement from Baseline Best Corrected Visual Acuity in the Study Eye (Pooled, CRVO Study Population)**

Visit	OZURDEX <sup>®</sup> N = 136	Sham N = 147	Difference
Day 30	21.3% *	6.8%	14.5%
Day 60	28.7% *	8.8%	19.8%
Day 90	17.6%	10.2%	7.4%
Day 180	18.4%	12.2%	6.1%

\* Proportion significantly higher with OZURDEX<sup>®</sup> compared to sham ( $p < 0.001$ )

The proportion of patients with vision loss from baseline of  $\geq 15$ -letter in BCVA was smaller with OZURDEX<sup>®</sup> as compared to sham (maximum difference of 7.2% at day 60).

**Table 8 Proportion of Patients with  $\geq 15$ -letter Vision Loss from Baseline BCVA (Pooled, CRVO Study Population)**

Visit	OZURDEX <sup>®</sup> N = 136	Sham N = 147	Difference
Day 30	3.7%	6.8%	<b>-3.1%</b>
Day 60	3.7%*	10.9%	<b>-7.2%</b>
Day 90	8.1%	13.6%	<b>-5.5%</b>
Day 180	14.0%	20.4%	<b>-6.4%</b>

\* Proportion statistically significantly lower with OZURDEX<sup>®</sup> compared to sham ( $p \leq 0.02$ )

The mean change from baseline BCVA was statistically significantly greater with OZURDEX<sup>®</sup> compared to sham up to day 90. The improvements peaked at day 60 with a difference among groups of 9.3 letters (Table 9) in favour of OZURDEX<sup>®</sup> as compared to the sham.

**Table 9****Baseline and Mean Change from Baseline in Number of Letters Read Correctly (Pooled, CRVO Study Population)**

	<b>OZURDEX®</b> <b>N=136</b>	<b>Sham</b> <b>N=147</b>	<b>Difference</b>
<b>Baseline</b>	52.4	53.3	-
<b>Change from baseline</b>			
Day 30	7.2*	0.4	<b>6.9</b>
Day 60	8.7*	-0.5	<b>9.3</b>
Day 90	4.2*	-0.4	<b>4.6</b>
Day 180	0.1	-1.8	<b>1.9</b>

\* Mean change from baseline statistically significantly greater with OZURDEX® compared to sham ( $p \leq 0.005$ )

**Indication of Posterior Segment Uveitis**

The efficacy of a single injection of OZURDEX® was assessed in a 6-month single, multicenter, masked, randomized study for the treatment of non-infectious uveitis affecting the posterior segment of the eye (study 206207-014).

Approximately 80% of patients had intermediate uveitis and 20% posterior uveitis. At baseline, 83% of patients had a vitreal haze score of +1.5 to 2, and 17% a score of +3 or +4. Over 40% of patients in each treatment group had received medications for the treatment of ocular inflammation in the study eye prior to the trial.

The efficacy analysis using the ITT population (with Last Observation Carried Forward for missing values), showed that after a single injection, the percent of patients reaching a vitreous haze score of 0 (where a score of 0 represents no inflammation) was statistically significantly greater for patients receiving OZURDEX® versus sham at week 8 (primary time point) and persisting through week 26. Additionally, the proportion of patients showing  $\geq 2$ -unit improvement from baseline in vitreous haze score, and the proportion of patients with  $\geq 15$  letters improvement from baseline in best-corrected visual acuity (BCVA) were statistically significantly higher with OZURDEX® compared to sham throughout the 26-week period (Table 10).



**Table 10 Comparison of Efficacy Results for OZURDEX® (N=77) vs. Sham (N=76) / p-value\***

	<b>Primary efficacy endpoint</b>	<b>Secondary efficacy endpoints</b>	
<b>Study Week</b>	<b>Percent of patients with vitreous haze score of 0</b>	<b>Percent of patients with <math>\geq</math> 15-letter improvement in BCVA from baseline</b>	<b>Percent of patients with <math>\geq</math> 2-unit improvement from baseline in vitreous haze score</b>
<b>Week 3</b>	23% vs. 12% 0.061	33% vs. 4% < 0.001	21% vs. 8% 0.023
<b>Week 6</b>	43% vs. 9% < 0.001	42% vs. 8% < 0.001	40% vs. 12% < 0.001
<b>Week 8</b>	47% vs. 12% < 0.001	43% vs. 7% < 0.001	44% vs. 12% < 0.001
<b>Week 12</b>	46% vs. 13% < 0.001	42% vs. 13% < 0.001	42% vs. 13% < 0.001
<b>Week 16</b>	40% vs. 21% 0.01	39% vs. 13% < 0.001	40% vs. 17% 0.002
<b>Week 20</b>	39% vs. 20% 0.009	40% vs. 13% < 0.001	42% vs. 15% < 0.001
<b>Week 26</b>	31% vs. 15% 0.014	38% vs. 13% < 0.001	34% vs. 12% 0.001

\*p-values were based on Pearson’s chi-square test or Fisher’s exact test.

**Indication of Diabetic Macular Edema (DME)**

The clinical efficacy of OZURDEX® was assessed in 2 phase 3 randomized, masked, sham-controlled studies (Studies 206207-010 and 206207-011) in patients with diabetic macular edema. A total of 1,048 patients (351 OZURDEX®, 347 DEX 350, and 350 sham) were evaluated as the ITT population and received up to 7 treatments during the 3-year study period.

A clinical benefit was established in these two studies in the ITT population. In patients with a phakic study eye, however, vision improvement was confounded by cataract formation or progression which occurred on average during the 2<sup>nd</sup> year of the study and was not reestablished until the cataract was removed. The group which benefited from OZURDEX® treatment the most were patients who were pseudophakic at baseline, and therefore, only the results in this patient population are presented below.

In the pooled subgroup of patients with a pseudophakic study eye at baseline, the proportion of patients with 15 or more letters improvement in BCVA from baseline was significantly higher with DEX 700 (23.3%) compared with Sham (10.9%) at the year 3/final visit, p = 0.024.

The mean BCVA average change from baseline during the study (AUC approach) was significantly greater with DEX 700 (6.5 letters) compared to Sham (1.7 letters), p < 0.001.

The mean average decrease from baseline in OCT central subfield retinal thickness during the study (AUC approach) was significantly greater with DEX 700 (131.8  $\mu\text{m}$ ) compared to Sham (50.8  $\mu\text{m}$ ),  $p < 0.001$ .

The efficacy results for the pseudophakic patients subgroup by study and pooled analyses are presented in Table 11 below.


**Table 11 Efficacy in Pseudophakic Patients (Studies 206207-010, 206207-011, and Pooled Analyses)**

Endpoint	Study 206206-010		Study 206206-011		Pooled Studies -010 and -011	
	DEX 700 (N = 44)	Sham (N = 50)	DEX 700 (N = 42)	Sham (N = 51)	DEX 700 (N = 86)	Sham (N = 101)
BCVA $\geq$ 15-letter improvement from baseline at year 3/final visit (%)	34.1	16.0	11.9	5.9	23.3	10.9
P-value	0.042		0.461		0.024	
Mean BCVA average change over 3 years, AUC approach (letters)	8.1	2.1	4.9	1.3	6.5	1.7
P-value	< 0.001		0.018		< 0.001	
OCT retinal thickness at center subfield mean average change over 3 years, AUC approach ( $\mu\text{m}$ )	-137.4	-43.3	-125.9	-58.3	-131.8	-50.8
P-value	< 0.001		0.007		< 0.001	

AUC = area under the curve; BCVA = best-corrected visual acuity; OCT = optical coherence tomography

Source: CSR 206207-010, Tables 14.5-14.2, 14.5-14.4, and 14.2-10.9, CSR 206207-011, Tables 14.5-14.2, 14.5-14.4, and 14.2-10.9; Module 5.3.5.3, ISE Tables 2-209.2, 2-209.4, and 2-5.7

**Figure 1** Proportion of Patients With 15 or More Letters Improvement in BCVA From Baseline by Visit (Pooled Studies 206027-010 and 206207-011, Pseudophakic Patient Subpopulation)



## DETAILED PHARMACOLOGY

### Pharmacodynamics

The OZURDEX<sup>®</sup> implant is a biodegradable polymer matrix containing micronized dexamethasone, a potent glucocorticoid which is the pharmacologically-active component of OZURDEX<sup>®</sup>. It is administered to the vitreous cavity via the OZURDEX<sup>®</sup> Applicator system, where it is released from the polymer matrix and is available within the vitreous to diffuse to retinal target cells and bind with high affinity to the glucocorticoid receptor. The end result is the upregulation or down-regulation of multiple proteins, many of which are responsible for the potent anti-inflammatory and immunosuppressant properties of dexamethasone.

Vascular endothelial growth factor (VEGF) is a vasoactive cytokine that has been linked to macular edema and that promotes the breakdown of the blood-retinal and blood-aqueous barriers. Glucocorticoids, such as dexamethasone and triamcinolone acetonide, were shown to suppress the expression of VEGF protein.

### Pharmacokinetics

In a 6 month monkey study following a single intravitreal injection of OZURDEX<sup>®</sup> the dexamethasone vitreous humor C<sub>max</sub> was 100 ng/mL at day 42 post-injection and 5.57ng/mL at day 91. The rank order of dexamethasone concentration was retina > iris > ciliary body > vitreous humor > aqueous humor > plasma.

In an *in vitro* melanin binding study, dexamethasone did not demonstrate any significant binding to synthetic melanin. In an *in vitro* metabolism study, following the incubation of [<sup>14</sup>C]-

dexamethasone with human cornea, iris-ciliary body, choroid, retina, vitreous humour, and sclera tissues for 18 hours, no metabolites were observed.

## **TOXICOLOGY**

No mutagenicity, carcinogenicity, reproductive or developmental toxicity studies are available for OZURDEX<sup>®</sup>.

Five toxicology studies were performed with for the assessment of the toxicity of OZURDEX<sup>®</sup>. Three were single-dose toxicity studies in New Zealand White (NZW) rabbits (two studies with duration of 7 weeks (X7I062G and X8I310G) and one with a duration of 9 month (P0701002)). In addition, two 9-month repeat-dose studies were performed (one in NZW rabbits (TX05030), and one in Cynomolgus monkeys (TX05029)).

Lens opacities were noted in the 9-month rabbit study (Study TX05030), but were not observed in any of the other studies. In all the studies, there were no significant or unexpected other drug-related ocular adverse effects.

In one rabbit study (Study P0701002) transient systemic effects were noted: decrease in body weight, lymphoid depletion (thymus, cecal tonsils and spleen), hepatocellular swelling and degeneration, atrophy of the adrenal glands, increases in serum levels of alkaline phosphatase, alanine aminotransferase, and cholesterol. Changes in serum levels of creatinine, total protein, and globulin levels were also noted. No systemic effects were noted in the other toxicity studies. Note that these effects were transient and reversible after day 60 or 90.

### ***Carcinogenicity***

No carcinogenicity studies on OZURDEX<sup>®</sup> or dexamethasone have been performed.

### ***Mutagenicity***

No studies of the mutagenic potential of OZURDEX<sup>®</sup> have been conducted. Studies evaluating the mutagenic potential of dexamethasone in bacteria and mammalian cells in vitro have been negative. An in vivo mouse micronucleus test was also negative. The polymer used in OZURDEX<sup>®</sup> has been widely used in implantable medical devices.

### ***Reproductive and Developmental Toxicity***

No studies of the reproductive or developmental toxicity are available for OZURDEX<sup>®</sup>.

Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application. In the mouse, corticosteroids produce fetal resorptions and a specific abnormality, cleft palate. In the rabbit, corticosteroids have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc. Pregnant rhesus monkeys treated with dexamethasone sodium phosphate intramuscularly at 1.0 mg/kg/day every other day for 28 days or at 10.0 mg/kg/day once or every other day on 3 or 5 days between gestation Days 23 and 49 had fetuses with findings limited to minor cranial abnormalities. A

1.0 mg/kg/day dose in pregnant rhesus monkeys would be approximately 85 times higher than a 700 µg DEX PS DDS<sup>®</sup> implant in humans (assuming 60 kg body weight).

## REFERENCES

1. Study 206207-008: A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion 6-month report. Allergan, Inc. November 2008.
2. Study 206207-009: A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion 6-month report. Allergan, Inc. November 2008.
3. Study: 206207-014: An 8-Week, Multicenter, Masked, Randomized Trial (with an 18-Week Masked Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS<sup>®</sup>) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Posterior Segment in Patients with Intermediate or Posterior Uveitis. Allergan, Inc. September 2009.
4. Anderson JM , Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. *Adv Drug Deliv Rev* 1997;28:5-24.
5. Boyd SR, Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides. *Surv Ophthalmol* 2001;46:209–233.
6. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. *Ophthalmology* 1995;102:1425-1433.
7. Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. *Arch Ophthalmol* 1997;115:486–491.
8. Cummings DM, Larijani GE, Conner DP, Ferguson RK, Rocci ML Jr. Characterization of dexamethasone binding in normal and uremic human serum. *DICP* 1990;24:229-231.
9. Deane JS, Rosenthal AR. Course and complications of intermediate uveitis. *Acta Ophthalmol Scand* 1997;75:82-84.
10. Decadron<sup>®</sup> [package insert]. Whitehouse Station, New Jersey: Merck & Co., Inc.; 2004.
11. Deschenes J, Murray PI, Rao NA, Nussenblatt RB; International Uveitis Study Group. International Uveitis Study Group (IUSG): clinical classification of uveitis. *Ocul Immunol Inflamm* 2008;16:1-2.
12. Diamond JG. Intraocular management of endophthalmitis: a systematic approach. *Arch Ophthalmol* 1981;99:96-99.
13. European Medicines Agency. Dexamethasone Summary Report (2). Maximum Residual Limits; 2001.
14. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. *J Pharmacol Exp Ther* 1996;277:105-112.
15. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Whua W, et al. Safety of an

- intravitreal injection of triamcinolone: results from a randomized clinical trial. *Arch Ophthalmol* 2004;122:336-340.
16. Gordon DM. Dexamethasone in ophthalmology. *Am J Ophthalmol* 1959;48:656-660.
  17. Gum GG, Gelatt KN, Ofri R. Physiology of the eye. In: Gelatt KN, ed. *Veterinary Ophthalmology*. Baltimore, Maryland: Lippincott Williams & Wilkins; 1999:151-181.
  18. Hare LE, Yeh KC, Ditzler CA, McMahon FG, Duggan DE. Bioavailability of dexamethasone. II: Dexamethasone phosphate. *Clin Pharmacol Ther* 1975;18:330-337.
  19. Health Outcome Appendix 206207-014. An 8-Week, Multicenter, Masked, Randomized Trial (with an 18-Week Masked Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DES PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Posterior Segment in Patients with Intermediate or Posterior Uveitis. Health Outcomes Report, Study Number 206207-014.
  20. Inatani M, Iwao K, Kawaji T, Hirano Y, Ogura Y, Hirooka K, et al. Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study. *Am J Ophthalmol* 2008;145:676-681.
  21. Jabs DA and Akpek EK. Immunosuppression for posterior uveitis. *Retina* 2005;25:1-18.
  22. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. *Am J Ophthalmol* 2000;130:492-513.
  23. Jamshidi K, Hyon S-H, Nakamura T, Ikada Y, Shimizu Y, Teramatsu T. In vitro and in vivo degradation of poly-l-lactide fibers. In: Christel P, Meunier A, Lee AJC, eds. *Biological and biomechanical performance of biomaterials*. Amsterdam: Elsevier Science Publishers BV; 1986:227-232.
  24. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. *Prog Ret Eye Res* 2005;24:587-611.
  25. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R. Intractable glaucoma following intravitreal triamcinolone in central vein occlusion. *Am J Ophthalmol* 2004;137:758-760.
  26. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreal dexamethasone drug delivery system in patients with persistent macular edema. *Arch Ophthalmol* 2007;125:309-317.
  27. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. *Arch Ophthalmol* 1992;110:259-266.
  28. Careen Lowder, MD, PhD; Rubens Belfort Jr, MD; Sue Lightman, MD; C. Stephen Foster, MD; Michael R. Robinson, MD; Rhett M. Schiffman, MD, MS, MHSA; Xiao-Yan Li, MD; Harry Cui, PhD; Scott M. Whitcup, MD; for the Ozurdex HURON Study Group. Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis. *Arch Ophthalmol*. 2011;129(5):545-553.

29. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. *Am J Ophthalmol* 1996;121:35-46.
30. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. *Clin Pharmacol Ther* 2000;68:356-366.
31. Nussenblatt RB. The natural history of uveitis. *Int Ophthalmol* 1990;14:303–308.
32. Nussenblatt RB, Palestine AG. Uveitis: Fundamentals and Clinical Practice. Chicago, Illinois; London, United Kingdom; Boca Raton, Florida: Year Book Medical Publishers, Inc; 1989.
33. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. *Ophthalmology* 1985;92:467-471.
34. Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. *Korean J Ophthalmol* 2005;19(2):122-127.
35. Peets EA, Staub M, Symchowicz S. Plasma binding of betamethasone-<sup>3</sup>H, dexamethasone-<sup>3</sup>H, cortisol-<sup>14</sup>C - A comparative study. *Biochem Pharmacol* 1969;18:1655-1663.
36. Peyman GA, Herbst R. Bacterial endophthalmitis. *Arch Ophthalmol* 1974;91:416-418.
37. Rohdewald P, Möllmann H, Barth J, Rehder J, Derendorf H. Pharmacokinetics of dexamethasone and its phosphate ester. *Biopharm Drug Dispos* 1987;8:205-212.
38. Rosenblum C, Dengler RE, Geoffroy RF. Ocular absorption of dexamethasone phosphate disodium by the rabbit. *Arch Ophthalmol* 1967;77:234-237.
39. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. *Arch Ophthalmol* 2003;121:1279-1282.
40. Shahid H, Hossain P, Amoaku WM. The management of retinal vein occlusion: is interventional ophthalmology the way forward? *Br J Ophthalmol* 2006;90:627-639.
41. Siebe H, Baude G, Lichtenstein I, Wang D, Bühler H, Hoyer G-A, et al. Metabolism of dexamethasone: sites and activity in mammalian tissues. *Renal Physiology Biochem* 1993;16:79-88.
42. Sutter FK, Gilles MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. *Br J Ophthalmol* 2003;87:972-974.
43. Tomlison ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism in vitro: species differences. *J Steroid Biochem Molec Biol* 1997;62:345-352.
44. Vicryl® [package insert]. Somerville, New Jersey: Ethicon, Inc.; 1996.
45. Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE, Argentieri GJ. Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. *J Biomed Mater Res* 1985;19:349-365.
46. Weijtens O, Feron EJ, Schoemaker RC, Cohen AF, Lentjes EG, Romijn FP, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. *Am J Ophthalmol* 1999;128:192-197.
47. Weijtens O, Schoemaker RC, Lentjes EG, Romijn FP, Cohen AF, van Meurs JC. Dexamethasone concentration in the subretinal fluid after a subconjunctival injection,



- a peribulbar injection, or an oral dose. *Ophthalmology* 2000;107:1932-1938.
48. Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. *Ophthalmology* 2002;109:1887-1891.
  49. Weijtens O, van der Sluijs FA, Schoemaker RC, Lentjes EG, Cohen AF, Romijn FP, et al. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. *Am J Ophthalmol* 1997;123:358-363.
  50. Weisbecker CA, Fraunfelder FT, Naidoff M, Rhee D, Tippermann R, eds. 1999 Physicians' Desk Reference for Ophthalmology, 27th ed. Montvale, New Jersey: Medical Economics Company, 1998; 7-8, 278-279.
  51. Yasukawa T, Ogura Y, Kimura H, Sakurai E, Tabata Y. Drug delivery from ocular implants. *Expert Opin Drug Deliv* 2006;3:261-273.
  52. Zierhut M, Foster CS. Multiple sclerosis, sarcoidosis and other diseases in patients with pars planitis. *Dev Ophthalmol* 1992;23:41-47.

**READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE  
PATIENT MEDICATION INFORMATION**

**PrOZURDEX®  
Dexamethasone intravitreal implant**

Read this carefully before you start taking **OZURDEX®** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **OZURDEX®**.

**What is OZURDEX® used for?**

OZURDEX® is used to treat:

- a condition called macular edema that is caused by a blockage of veins in the eye.
- a condition called non-infectious uveitis of the posterior segment of the eye that is not caused by an eye infection.
- a condition called diabetic macular in patients who have had cataract surgery and intraocular lens implantation.

These conditions cause swelling in the back part of your eye, which leads to vision changes and vision loss.

**How does OZURDEX® work?**

OZURDEX® works by reducing swelling of the macula. This helps to lessen or prevent more damage to the macula. The macula is an area in the centre of the back part of the eye. It is responsible for clear vision.

OZURDEX® also works by reducing the inflammation in the back part of the eye.

**What are the ingredients in OZURDEX®?**

Medicinal ingredients: dexamethasone.

Non-medicinal ingredient(s): A polymer drug delivery system contains PLGA biodegradable polymer matrix (NOVADUR™): Resomer® RG 502, Poly (D,L-lactide-co-glycolide), 50:50 PLGA ester terminated; and Resomer® RG 502 H, Poly (D,L-lactide-co-glycolide),50:50 PLGA acid terminated.

**OZURDEX® comes in the following dosage forms:**

As an intravitreal implant that contains 0.7 mg dexamethasone. Intravitreal means that this implant is placed into the eye through an injection.

**Do not use OZURDEX® if:**

- you are allergic to dexamethasone or any of the other ingredients in OZURDEX®
- you are allergic to other medicines like OZURDEX®, called corticosteroids
- you have an eye infection of any kind caused by bacteria, a virus or a fungus
- you have glaucoma that is at an advanced stage
- you have aphakic eyes (eyes without natural or artificial lens) along with a tear in the posterior lens capsule of your eye
- you have a condition called Anterior Chamber Intraocular Lens (ACIOL) along with a tear in the posterior lens capsule of your eye

Ask your doctor if you are not sure if you have any of the conditions listed above.

The use of OZURDEX® in children and adolescents is not recommended.

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take OZURDEX®. Talk about any health conditions or problems you may have, including if:**

- you have aphakic eyes (eyes without natural or artificial lens)
- you have a tear in the posterior lens capsule of your eye
- you have had a herpes simplex infection in your eye before (an ulcer on the eye that has been there a long time, or sores on the eye);
- you are taking any medication to thin the blood or any other medication
- you are pregnant or planning to become pregnant;
- you are breast feeding or planning to breast feed;
- you had recent eye surgery, or plan to have one;

**Other warnings you should know about:**

The following may occur or get worse after OZURDEX® treatment:

- an infection inside or around the eye
- redness (inflammation) inside the eye
- glaucoma and/or increased pressure in the eye
- detachment of the layer in the back of the eye (retinal detachment), or
- clouding of the lens (cataract)
- misplacement of implant that requires surgical intervention

It is important to identify and treat these conditions listed directly above as soon as possible. Please tell your doctor immediately if you have any concerns with your eye or experience any of the following signs:

- Blurred or decreased vision
- Eye pain or increased discomfort
- Worsening eye redness
- A feeling of spots in front of the eye (called 'floaters')
- Increased sensitivity to light

In some patients the pressure in the eye may increase right after OZURDEX® is implanted into the eye. This is something you may not notice, so your doctor might monitor this after OZURDEX® is implanted.

*Driving and using machines:*

After OZURDEX® treatment you may experience some blurred vision for a short time. Wait until you can see clearly before driving or using machines.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

The following medicines may interact with OZURDEX®:

- Medicines used to thin your blood called blood thinners.
- Sedatives and sleep-inducing medicines called barbiturates.
- Rifampin, which is a medicine used to treat tuberculosis.
- Ketoconazole, which is a medicine used to treat fungal infections.
- Indinavir, which is a medicine used to treat HIV infection.
- Medicines used to treat seizures, like phenytoin or carbamazepine.
- Erythromycin, which is an antibiotic.

### How to take OZURDEX®?

- OZURDEX® will be given to you by a doctor, called an ophthalmologist, who has experience in giving injections into the eye.
- It will be implanted directly into your eye through an injection.
- It is not recommended that both of your eyes be injected with OZURDEX® at the same time.
- After you receive the injection, your doctor will check your eye.
- You may be given antibiotic eye drops to use before, during or after your injection to prevent eye infections.
- You may also be given a pain medicine on the day of your injection.
- You may hear a 'click' during the injection of OZURDEX®; you should not move, as this is expected.
- Follow all instructions given to you by your doctor.

### Usual dose:

The usual dose is one OZURDEX® implant to be given by injection into your eye. Your doctor will decide if you should receive another OZURDEX injection. If you need another injection, your doctor will wait 6 months to give it to you.

### Overdose:

If you think you have taken too much OZURDEX®, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

### Missed Dose:

If you miss your appointment to receive OZURDEX®, contact your doctor or hospital as soon as possible to reschedule your appointment.

### What are possible side effects from using OZURDEX®?

These are not all the possible side effects you may feel when taking OZURDEX®. If you experience any side effects not listed here, contact your healthcare professional.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<b>VERY COMMON</b>			
Increased pressure in the eye		x	
Glaucoma (serious eye disease where pressure in the eye is increased): blurred vision, eye redness, halos around lights, loss of vision, nausea, severe eye pain, vomiting.		x	
Cataracts (clouding of the lens of your eye): blurry vision, clouded vision, eye pain, fading or yellowing of colours, seeing halos and glare around lights, trouble seeing at night		x	
Bleeding on the surface of the eye*	x		
<b>COMMON</b>			
Vitreous detachment (detachment of the jelly inside the eye from the light-sensitive layer at the back of the eye): seeing flashes and floaters		x	
Bleeding into the inside of the eye*: blurry or		x	

blocked vision, floaters			
Vision blurred, decreased or difficulty seeing clearly		x	
A feeling of spots in front of the eye (including 'floaters')*	x		
Abnormal feeling in the eye	x		
Eye pain*		x	
Inflammation and itchiness of the eyelid	x		
Migraine	x		
Seeing flashes of light		x	
Swelling on the surface of the eye*	x		
A feeling of looking through mist or fog*		x	
Difficulties in seeing clearly		x	
Redness of the white of the eye	x		
<b>RARE</b>			
Tear in the retina: vision loss or difficulty seeing		x	
Anterior chamber flare (increased protein in the front of the eye due to inflammation): blurry vision	x		
Headache		x	
A severe inflammation at the back of the eye (usually due to viral infection): eye redness, pain in your eyeball, sensitive to light, and vision loss		x	x
Severe infection and Inflammation inside the eye: eye pain, redness, visual loss		x	
<b>UNKNOWN FREQUENCY</b>			
Implant migrated from the back to the front part of the eye: blurry vision		x	
Low eye pressure	x		

\*Some of these side effects could have been caused by the injection procedure or the OZURDEX implant itself

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

<p><b>Reporting Side Effects</b></p> <p>You can report any suspected side effects associated with the use of health products to Health Canada by:</p> <ul style="list-style-type: none"> <li>• Visiting the Web page on Adverse Reaction Reporting (<a href="http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php">http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php</a>) for information on how to report online, by mail or by fax; or</li> <li>• Calling toll-free at 1-866-234-2345.</li> </ul> <p><i>NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.</i></p>
--

**Storage:**

Keep out of the reach and sight of children.

Store at room temperature between 15° C and 30° C. Protect from excessive heat.

**If you want more information about OZURDEX®:**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<http://hc-sc.gc.ca/index-eng.php>); the manufacturer's website: [www.allergan.ca](http://www.allergan.ca), or by calling 1-800-668-6424.

This leaflet was prepared by Allergan Inc.

Last revised: August 21, 2019

©2019 Allergan Inc., Markham, ON L6G 0B5. ®Marks owned by Allergan Inc. All rights reserved.